PeerView Internal Medicine CME/CNE/CPE Audio Podcast - Toni K. Choueiri, MD - How I Think, How I Treat: Understanding and Working With New Immunotherapeutic and Targeted Management Models in Advanced RCC

Toni K. Choueiri, MD - How I Think, How I Treat: Understanding and Working With New Immunotherapeutic and Targeted Management Models in Advanced RCC

02/19/20 • 37 min

PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Go online to PeerView.com/KWJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The treatment armamentarium for advanced renal cell carcinoma (RCC) has undergone rapid expansion with the validation of novel multitargeted tyrosine kinase inhibitor (TKI) and immune checkpoint inhibitor therapies. More recently, the emergence of dual checkpoint blockade and immunotherapy-TKI combinations in RCC has increased the number of treatment choices in the frontline setting, allowed for greater flexibility when selecting second-line agents, and sparked additional research into TKI and immune checkpoint inhibitor options in earlier disease settings. In the wake of these advances, understanding how to effectively select and sequence newer regimens through multiple lines of therapy while ensuring safe usage is crucial to maximize beneficial patient outcomes throughout the advanced RCC continuum. This unique “How I Think, How I Treat” educational on-demand activity, based on an event held adjunct to the 18th International Kidney Cancer Symposium, features personal insights from leading kidney cancer experts on how they are adapting their own practice based on the evidence supporting optimized care in advanced RCC in the context of patient-, disease-, and treatment-specific factors, as well as how the innovations fueling modern approaches to care are improving outcomes for patients with RCC. Upon completion of this activity, participants should be better able to: Assess the latest evidence and clinical implications of novel approaches, including new multitargeted tyrosine kinase inhibitors (TKIs), immune checkpoint inhibitors, and combination therapies in advanced renal cell carcinoma (RCC), Select optimal frontline treatment options among TKIs and combination approaches (dual checkpoint inhibition or targeted agents plus immune checkpoint inhibitors) for individual patients with advanced RCC based on relevant patient- and disease-related characteristics, including in the context of clinical trial enrollment, Apply validated targeted therapy and immunotherapy options effectively for patients with pretreated advanced RCC through multiple lines of therapy that reflect considerations of prior treatment history and patient comorbidities, Employ effective strategies to prevent and/or manage treatment-related complications with multitargeted TKIs and immune checkpoint inhibitor therapy in patients with RCC

Previous Episode

undefined - Andre H. Goy, MD - How I Think, How I Treat: BTK Inhibitors as a Clinical Strategy in CLL, MCL, and Beyond—Therapeutic Selection, Sequencing, and Next Steps

Andre H. Goy, MD - How I Think, How I Treat: BTK Inhibitors as a Clinical Strategy in CLL, MCL, and Beyond—Therapeutic Selection, Sequencing, and Next Steps

Go online to PeerView.com/FKM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. First- and second-generation Bruton tyrosine kinase (BTK) inhibitors have transformed the therapeutic landscape of several lymphoid cancers, including chronic lymphocytic leukemia (CLL), and mantle cell lymphoma (MCL). The present and future management of these diseases will increasingly be defined by the integration of BTK inhibitors—along with other novel therapeutics—into management protocols that have previously been characterized by the use of immunochemotherapy-focused options. Several important practical issues arising from the use of BTK inhibitors, ranging from the initial therapy selection to therapeutic sequencing and use of active combinations, will continue to be a part of patient management for years to come. This PeerView Live “How I Think, How I Treat” on-demand activity, based on a satellite symposium preceding the 61st ASH Annual Meeting and Exposition, exposes learners to the personal insights of several experts in the field and includes in-depth analyses of the cutting-edge science on the present and future role of BTK inhibitors in CLL, MCL, and other lymphoid cancers. Key topics include BTK inhibitor sequencing, selecting patients for treatment, differentiating among first- and second-generation compounds, and safety management. Ultimately, this event provides a “virtual mentorship” experience on the use of BTK inhibitors in several different diseases. Upon completion of this activity, participants should be better able to: Describe updated evidence regarding the use of first- and second-generation BTK inhibitors in the management of B-cell NHL, including agent potency/selectivity, response data, survival outcomes, and activity in BTK inhibitor–intolerant or –resistant disease, Recommend personalized therapy with BTK inhibitors for patients across the spectrum of B-cell malignancies, including chronic lymphocytic leukemia and mantle cell lymphoma, among others, Manage unique safety considerations associated with BTK inhibitor therapy in patients with B-cell NHL

Next Episode

Paul P. Doghramji, MD - Relieving the Burden of Insomnia - Improving Recognition and Treatment in the Primary Care Setting

Go online to PeerView.com/HQB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in insomnia management discusses strategies for improving the recognition and treatment of insomnia in the primary care setting. Upon completion of this activity, participants should be better able to: Describe the impact of insomnia on quality of life and risk of psychiatric and physical illnesses, Differentially diagnose insomnia from other sleep disorders, Identify tolerance and dependency issues and adverse events associated with available insomnia therapies, Apply the latest clinical data on novel and emerging therapies, including dual orexin receptor antagonists, to the treatment of patients with insomnia